ALXN1840 Phase 3 Data Shows Significant Neurologic & Global Benefit in Wilson Disease
MNPR has more than doubled off its 52-week low of $29.18 on elevated volume (1.8× avg).
Summary
Monopar Therapeutics presented new analyses from its Phase 3 FoCus trial for ALXN1840 in Wilson disease, demonstrating significant neurologic improvement (p=0.006) and greater global clinical benefit (p<0.001) compared to standard of care. These findings build on previously reported positive Phase 3 results and further strengthen the efficacy profile of their lead candidate, particularly in addressing critical neurological symptoms. This positive data enhances the drug's prospects for regulatory approval. The company plans to submit a New Drug Application (NDA) to the FDA in mid-2026.
At the time of this announcement, MNPR was trading at $87.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $587.4M. The 52-week trading range was $29.18 to $105.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.